Drug Trial Radar · NCT07391657
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
508
Planned (sponsor's estimate)
Start
Feb 23, 2026
Primary completion
Jun 14, 2028
Study completion Jul 29, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.
Conditions
- Relapsed Refractory Multiple Myeloma
Interventions
AZD0120Biological
CAR-T Cells
DaratumumabDrug
Daratumumab
CarfilzomibDrug
Carfilzomib
DexamethasoneDrug
Dexamethasone
BortezomibDrug
Bortezomib
PomalidomideDrug
Pomalidomides
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM.Time frame: 3 years
- To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of MRD negativity rate at 9 months in participants with RRMM.Time frame: 2 years
Locations
143 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Gilbert, Arizona · Not yet recruiting
Research Site
Phoenix, Arizona · Withdrawn
Research Site
Tucson, Arizona · Not yet recruiting
Research Site
La Jolla, California · Withdrawn
Research Site
Sacramento, California · Not yet recruiting
Research Site
Santa Monica, California · Not yet recruiting
Research Site
Denver, Colorado · Recruiting
Research Site
New Haven, Connecticut · Recruiting
Research Site
Washington D.C., District of Columbia · Not yet recruiting
Research Site
Coral Gables, Florida · Withdrawn
Research Site
Tampa, Florida · Not yet recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Park Ridge, Illinois · Not yet recruiting
Research Site
Iowa City, Iowa · Withdrawn
Research Site
Kansas City, Kansas · Not yet recruiting
Research Site
Louisville, Kentucky · Recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Boston, Massachusetts · Withdrawn
Research Site
Detroit, Michigan · Withdrawn
Research Site
Detroit, Michigan · Withdrawn
Research Site
Rochester, Minnesota · Withdrawn
Research Site
Albany, New York · Not yet recruiting
Research Site
New York, New York · Withdrawn
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Withdrawn
Research Site
New York, New York · Recruiting
Research Site
Rochester, New York · Withdrawn
Research Site
The Bronx, New York · Withdrawn
Research Site
Chapel Hill, North Carolina · Not yet recruiting
Research Site
Charlotte, North Carolina · Not yet recruiting
Research Site
Charlotte, North Carolina · Recruiting
Research Site
Winston-Salem, North Carolina · Recruiting
Research Site
Winston-Salem, North Carolina · Not yet recruiting
Research Site
Cincinnati, Ohio · Not yet recruiting
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Portland, Oregon · Not yet recruiting
Research Site
Charleston, South Carolina · Withdrawn
Research Site
Nashville, Tennessee · Recruiting
Showing 40 of 143 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.